AC Immune (ACIU) Amortization of Deferred Charges (2019 - 2022)
AC Immune (ACIU) posted quarterly Amortization of Deferred Charges of $407881.4 for Q4 2025, up 110.18% year-over-year from $194058.7 in Q4 2024, and up 19.52% quarter-over-quarter from $341279.9 in Q3 2025.
Powered by 
Analysis
AC Immune (ACIU) Amortization of Deferred Charges (2019 - 2022) Analysis & Trends
AC Immune (ACIU) has reported Amortization of Deferred Charges for 7 consecutive years, with $407881.4 the latest figure, recorded in Q4 2025.
- In Q4 2025, Amortization of Deferred Charges rose 110.18% year-over-year to $407881.4; the TTM figure through Dec 2025 stood at $1.3 million (up 74.43% YoY), while the FY2025 annual figure was $1.3 million, up 73.24% from the prior year.
- Amortization of Deferred Charges advanced to $407881.4 in Q4 2025 per ACIU's latest filing, from $341279.9 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $407881.4 in Q4 2025 and bottomed at $118348.3 in Q1 2021.
- Historically, Amortization of Deferred Charges has averaged $195683.2 across 5 years, with a median of $154656.3 in 2021.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges slipped 5.6% — and 2025, when it surged 110.18%.
- AC Immune's Amortization of Deferred Charges stood at $153999.3 in 2021, then decreased by 5.19% to $145999.4 in 2022, then grew by 6.56% to $155574.9 in 2023, then advanced by 24.74% to $194058.7 in 2024, then surged by 110.18% to $407881.4 in 2025.
- Business Quant data shows ACIU's Amortization of Deferred Charges at $407881.4 in Q4 2025, $341279.9 in Q3 2025, and $314051.5 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | -3,106.37 |
| Jun 30, 2022 | -2,076.59 |
| Mar 31, 2022 | -3,248.43 |
| Dec 31, 2021 | -3,253.51 |
| Sep 30, 2021 | -1,089.13 |
| Jun 30, 2021 | -2,193.29 |
| Mar 31, 2021 | -2,212.12 |
| Dec 31, 2020 | -2,212.31 |
| Sep 30, 2020 | -2,172.73 |
| Jun 30, 2020 | -1,037.81 |
| Mar 31, 2020 | -4,135.39 |
| Dec 31, 2019 | -26,269.97 |
| Sep 30, 2019 | 4,059.81 |
| Jun 30, 2019 | 9,973.08 |
| Mar 31, 2019 | -3,012.19 |